製品番号: HY-16106

Talazoparib

(別名: BMN-673; LT-673)

106 Cited Publications

カスタマーレビュー

Based on 106 publication(s) in Google Scholar

Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.85%
CAS 番号: 1207456-01-6
分子式: C₁₉H₁₄F₂N₆O
分子量:380.35

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Talazoparib 構造式

CAS 番号: 1207456-01-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (106)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

PARP2

0.87 nM (Ki)

PARP1

1.2 nM (Ki)

PARP アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
CAPAN-1	EC₅₀	5 nM Compound: (8S,9R)-47; BMN 673; Talazoparib	Cytotoxicity against BRCA2-deficient human Capan1 cells Cytotoxicity against BRCA2-deficient human Capan1 cells	[PMID: 26652717]
CAPAN-1	IC₅₀	1.8 nM Compound: 5; BMN-673	Antiproliferative activity against human Capan1 cells after 7 days by CCK8 or SRB assay Antiproliferative activity against human Capan1 cells after 7 days by CCK8 or SRB assay	[PMID: 28692916]
CAPAN-1	IC₅₀	686.09 nM Compound: TP	Antiproliferative activity against human Olaparib-resistant CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay Antiproliferative activity against human Olaparib-resistant CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay	[PMID: 37605459]
CAPAN-1	IC₅₀	7.77 nM Compound: TP	Antiproliferative activity against human CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay Antiproliferative activity against human CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay	[PMID: 37605459]
CAPAN-1	IC₅₀	906.45 nM Compound: TP	Antiproliferative activity against human Talazoparib-resistant CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay Antiproliferative activity against human Talazoparib-resistant CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay	[PMID: 37605459]
DLD-1	IC₅₀	0.002 μM Compound: 4	Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days	[PMID: 34570508]
DLD-1	IC₅₀	0.003 μM Compound: Talazoparib	Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis	[PMID: 37484567]
DLD-1	IC₅₀	0.004 μM Compound: Talazoparib	Cytotoxicity against human DLD1 cells expressing BRCA2 knockout assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis Cytotoxicity against human DLD1 cells expressing BRCA2 knockout assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis	[PMID: 37484567]
DLD-1	IC₅₀	0.006 μM Compound: Talazoparib	Cytotoxicity against human DLD1 cells expressing BRCA2 knockout assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis Cytotoxicity against human DLD1 cells expressing BRCA2 knockout assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis	[PMID: 37484567]
DLD-1	IC₅₀	0.122 μM Compound: Talazoparib	Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis	[PMID: 37484567]
DLD-1	IC₅₀	0.65 μM Compound: Talazoparib	Cytotoxicity against human DLD1 cells assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis Cytotoxicity against human DLD1 cells assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis	[PMID: 37484567]
DLD-1	IC₅₀	0.86 μM Compound: Talazoparib	Cytotoxicity against human DLD1 cells assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis Cytotoxicity against human DLD1 cells assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis	[PMID: 37484567]
HCC1395	IC₅₀	0.46 nM Compound: Talazoparib	Anticancer activity against human HCC1395 cells assessed as cell growth inhibition Anticancer activity against human HCC1395 cells assessed as cell growth inhibition	[PMID: 38838546]
HCT-116	IC₅₀	0.009 μM Compound: Talazoparib	Cytotoxicity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis Cytotoxicity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis	[PMID: 37484567]
HCT-116	IC₅₀	0.013 μM Compound: Talazoparib	Cytotoxicity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis Cytotoxicity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis	[PMID: 37484567]
HCT-116	IC₅₀	0.018 μM Compound: Talazoparib	Cytotoxicity against human HCT-116 cells expressing N-terminally truncated POR/copGFP/puramycin resistance genes assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition Cytotoxicity against human HCT-116 cells expressing N-terminally truncated POR/copGFP/puramycin resistance genes assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition	[PMID: 37484567]
HCT-116	IC₅₀	0.019 μM Compound: Talazoparib	Cytotoxicity against human HCT-116 cells expressing N-terminally truncated POR/copGFP/puramycin resistance genes assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by Cytotoxicity against human HCT-116 cells expressing N-terminally truncated POR/copGFP/puramycin resistance genes assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by	[PMID: 37484567]
HEK293	IC₅₀	4.95 nM Compound: 2; BMN-673	Cytotoxicity against HEK293 cells assessed as inhibition of cell viability Cytotoxicity against HEK293 cells assessed as inhibition of cell viability	[PMID: 33120078]
LoVo	EC₅₀	2.5 nM Compound: 9, BMN 673	Inhibition of PARP in human LoVo cells assessed as inhibition of hydrogen peroxide-induced PARylation treated for 30 mins prior to incubation with H2O2 for 5 mins by fluorescence analysis Inhibition of PARP in human LoVo cells assessed as inhibition of hydrogen peroxide-induced PARylation treated for 30 mins prior to incubation with H2O2 for 5 mins by fluorescence analysis	[PMID: 25761096]
LoVo	EC₅₀	2.51 nM Compound: (8S,9R)-47; BMN 673; Talazoparib	Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay	[PMID: 26652717]
LoVo	GI₅₀	4 nM Compound: (8S,9R)-47; BMN 673; Talazoparib	Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay	[PMID: 26652717]
MDA-MB-157	IC₅₀	0.37 nM Compound: Talazoparib	Anticancer activity against human MDA-MB-157 cells assessed as cell growth inhibition Anticancer activity against human MDA-MB-157 cells assessed as cell growth inhibition	[PMID: 38838546]
MDA-MB-436	IC₅₀	0.012 nM Compound: 2; BMN-673	Cytotoxicity against human MDA-MB-436 cells assessed as inhibition of cell viability incubated for 14 days with three intermittent intervals by CellTiterGlo luminescence assay Cytotoxicity against human MDA-MB-436 cells assessed as inhibition of cell viability incubated for 14 days with three intermittent intervals by CellTiterGlo luminescence assay	[PMID: 33120078]
MDA-MB-436	IC₅₀	0.38 nM Compound: 2; BMN-673	Cytotoxicity against human MDA-MB-436 cells assessed as inhibition of cell viability incubated for 4 days by CellTiterGlo luminescence assay Cytotoxicity against human MDA-MB-436 cells assessed as inhibition of cell viability incubated for 4 days by CellTiterGlo luminescence assay	[PMID: 33120078]
MDA-MB-436	IC₅₀	0.7 nM Compound: 5; BMN-673	Antiproliferative activity against human MDA-MB-436 cells after 7 days by CCK8 or SRB assay Antiproliferative activity against human MDA-MB-436 cells after 7 days by CCK8 or SRB assay	[PMID: 28692916]
MRC5	EC₅₀	0.31 μM Compound: (8S,9R)-47; BMN 673; Talazoparib	Cytotoxicity against human MRC5 cells Cytotoxicity against human MRC5 cells	[PMID: 26652717]
MX1	EC₅₀	0.3 nM Compound: (8S,9R)-47; BMN 673; Talazoparib	Cytotoxicity against BRCA1-deficient human MX1 cells Cytotoxicity against BRCA1-deficient human MX1 cells	[PMID: 26652717]
SUM149PT	EC₅₀	1.6 nM Compound: Talazoparib	Cytotoxicity against BRCA1-deficient human SUM149 cells measured after 6 days by microscopic analysis Cytotoxicity against BRCA1-deficient human SUM149 cells measured after 6 days by microscopic analysis	[PMID: 31042381]
SUM149PT	EC₅₀	23.2 nM Compound: Talazoparib	Cytotoxicity against BRCA1-proficient human SUM149 cells measured after 6 days by microscopic analysis Cytotoxicity against BRCA1-proficient human SUM149 cells measured after 6 days by microscopic analysis	[PMID: 31042381]
V79	IC₅₀	5011.4 nM Compound: 5; BMN-673	Cytotoxicity against BRCA2 expressing Chinese hamster V79 cells after 3 days by CCK8 or SRB assay Cytotoxicity against BRCA2 expressing Chinese hamster V79 cells after 3 days by CCK8 or SRB assay	[PMID: 28692916]

体外実験

Talazoparib shows an EC₅₀ of 2.51 nM in cellular PARylation assay^[1].
Talazoparib shows EC₅₀s of 0.3 nM, 5 nM and 0.31 for MX-1 cells (BRCA1 mutant), Capan-1 cells (BRCA2 mutant) and MRC-5 cells (normal)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Talazoparib (0.33 mg/kg; i.g.; once daily; for 28 days) exhibits antitumor activity against BRCA1 mutant breast cancer model in mice^[1].
Talazoparib exhibits moderate oral bioavailability (rat 56%) and C_max (rat 7948 ng/mL) following oral administration (rat 10 mg/kg)^[1]. Talazoparib exhibits the terminal elimination half-life (rat 2.25 h) due to plasma clearance (2 mL/min/kg) following intravenous administration (rat 5 mg/kg)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female athymic nu/nu mice (8-10 weeks old), with MX-1 xenograft-bearing mice^[1]
Dosage:

0.33 mg/kg
Administration:

Oral gavage, once daily, for 28 days
Result:

Significantly inhibited xenograft MX-1 tumor growth.

Animal Model:

Sprague-Dawley rats^[1]
Dosage:

5mg/kg for i.v.; 10 mg/kg for oral (Pharmacokinetic Analysis)
Administration:

Intravenous administration and oral administration
Result:

Oral bioavailability (56%), C_max (7948 ng/mL), T_1/2 (2.25 h).

化学情報

CAS 番号 1207456-01-6
性状 Solid
分子量 380.35
分子式 C₁₉H₁₄F₂N₆O
Color White to off-white
SMILES

O=C1NN=C2C3=C1C=C(F)C=C3N[C@H](C4=CC=C(F)C=C4)[C@H]2C5=NC=NN5C
別名

BMN-673; LT-673
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (106)

All 2D/3D Cell Culture and DifferentiationCell Proliferation/Viability AssayCell Imaging/StainingIn Vivo Efficacy StudyWB

Sort by:

Journal Impact Factor

Cancer Cell

Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors. [Abstract]

2020 Dec 14;38(6):844-856.e7. PMID: 33186520

Talazoparib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Dec 14;38(6):844-856.e7. [Abstract]

Talazoparib (0.1–1250 nM, 5 days) suppressed the viability of CXorf67-WT and -KO Daoy C67 cells.

Talazoparib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Dec 14;38(6):844-856.e7. [Abstract]

Talazoparib (5 nM, 0.5 or 24 h) combined with IR (2 Gy) resulted in further increases in γ-H2AX foci.

Talazoparib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Dec 14;38(6):844-856.e7. [Abstract]

Talazoparib (0.33 mg/kg, p.o., once a day for 5 days per week for 84 days) inhibited tumor growth in C67-KO and C67-re-expressing Daoy cells xenograft tumor models.
Cancer Discov

Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer. [Abstract]

2022 Aug 5;12(8):1904-1921. PMID: 35552618

Talazoparib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2022 Aug 5;12(8):1904-1921. [Abstract]

Talazoparib (0.33 mg/kg, p.o., 70 days) diminished ascites accumulation and extended survival by ~30% in mice bearing ATX-sufficient OvCa.
Cancer Discov

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. [Abstract]

2017 Sep;7(9):984-998. PMID: 28588062
Nat Cancer

Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. [Abstract]

2022 Oct;3(10):1211-1227. PMID: 36253486

Talazoparib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Oct;3(10):1211-1227. [Abstract]

Representative images of clonogenic assay results in PARP inhibitor (PARPi)-resistant OVCA433 cell in the presence of the indicated inhibitor for 12 d. ALKi, ALK inhibitor; LOR, Lorlatinib (250-500 nM); TALA, Talazoparib (100-200 nM); Comb, combination of Lorlatinib and Talazoparib.

Talazoparib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Oct;3(10):1211-1227. [Abstract]

Representative images of RAD51 with EdU/DAPI staining in OVCA433 cell treated with 0.25 μM PARP inhibitor (PARPi; Talazoparib) or 0.5 μM ALK inhibitor (ALKi; Lorlatinib), either alone or in combination, for 48 h.
Nat Genet

Multiparametric and accurate functional analysis of genetic sequence variants using CRISPR-Select. [Abstract]

2022 Dec;54(12):1983-1993. PMID: 36471068
Cancer Res

SMARCA4 loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer. [Abstract]

2025 May 14. PMID: 40366633
Cancer Res

SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer. [Abstract]

2023 Nov 15;83(22):3813-3826. PMID: 37695044
Cancer Res

Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate. [Abstract]

2021 Jul 1;81(13):3480-3494. PMID: 34127497
Drug Resist Updat

ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer. [Abstract]

2026 Jan:84:101319. PMID: 41192279
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Nat Commun

HR eye & MMR eye: one-day assessment of DNA repair-defective tumors eligible for targeted therapy. [Abstract]

2025 May 12;16(1):4239. PMID: 40355434
Nat Commun

Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide. [Abstract]

2023 Dec 9;14(1):8161. PMID: 38071218
Nat Commun

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. [Abstract]

2019 Jun 11;10(1):2556. PMID: 31186408
ACS Nano

Active Learning-Based Prediction of Drug Combination Efficacy. [Abstract]

2025 May 13;19(18):17929-17940. PMID: 40304271
Mol Cell

Ubiquitin Modification by the E3 Ligase/ADP-Ribosyltransferase Dtx3L/Parp9. [Abstract]

2017 May 18;66(4):503-516.e5. PMID: 28525742
Theranostics

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. [Abstract]

2020 Jul 25;10(21):9477-9494. PMID: 32863940
J Clin Invest

Precision screening facilitates clinical classification of BRCA2-PALB2 binding variants with benign and pathogenic functional effects. [Abstract]

2025 Apr 15;135(12):e181879. PMID: 40232841
J Clin Invest

Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. [Abstract]

2021 Jun 1;131(11):e146256. PMID: 34060485
Adv Sci (Weinh)

KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer. [Abstract]

2024 Sep;11(34):e2400140. PMID: 38973255
Adv Sci (Weinh)

In Situ Formation of Fibronectin-Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy. [Abstract]

2024 May;11(19):e2307940. PMID: 38482976
Sci Adv

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities. [Abstract]

2026 Jun 26;12(26):eadz3351. PMID: 42361179
Sci Adv

53BP1 orchestrates sequence feature of RAG targets to balance DNA repair outcomes during V(D)J recombination. [Abstract]

2026 May 22;12(21):eaec2231. PMID: 42172328
Sci Adv

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer. [Abstract]

Sci Adv. 2025 Apr 25;11(17):eadu0847. PMID: 40267193
Sci Adv

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. [Abstract]

2022 Feb 18;8(7):eabl9794. PMID: 35179959
Cancer Lett

2026 Feb 4;642:218300.
Cancer Lett

Targeting ATR signaling in sarcoma with homologous recombination deficiency. [Abstract]

2026 Apr 1:642:218300. PMID: 41651400
Cancer Lett

Pentagalloylglucose disrupts the PALB2-BRCA2 interaction and potentiates tumor sensitivity to PARP inhibitor and radiotherapy. [Abstract]

2022 Oct 10:546:215851. PMID: 35926819
Cancer Lett

XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a. [Abstract]

2021 Apr 10:503:197-212. PMID: 33493586
Cancer Lett

Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal cancer. [Abstract]

2021 Mar 1:500:208-219. PMID: 33232787
EBioMedicine

Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. [Abstract]

2020 Sep:59:102923. PMID: 32799124

Talazoparib purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2020 Sep:59:102923. [Abstract]

Western Blot analyses of TP53, p21 and RAD51 in PARP inhibitor sensitive (SKCO1 and LS513) and resistant cell lines (SW1222 and SNU61) after treatment with Talazoparib for 48 h. Talazoparib decreases RAD51 protein expression in the two TP53 wild-type cell lines SKCO1 and LS513.
EBioMedicine

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. [Abstract]

2018 Dec:38:47-56. PMID: 30472087
Clin Cancer Res

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors. [Abstract]

2017 Feb 15;23(4):1001-1011. PMID: 27559053
NPJ Precis Oncol

Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study. [Abstract]

2025 Nov 21;9(1):373. PMID: 41272086
NPJ Precis Oncol

Targeting USP8 causes synthetic lethality through degradation of FGFR2 in ARID1A-deficient ovarian clear cell carcinoma. [Abstract]

2025 Mar 12;9(1):69. PMID: 40074856
Proc Natl Acad Sci U S A

PARP12-mediated mono-ADP-ribosylation as a checkpoint for necroptosis and apoptosis. [Abstract]

2025 Jun 17;122(24):e2426660122. PMID: 40489618
Oncogene

A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. [Abstract]

2021 Oct;40(43):6143-6152. PMID: 34508175
Oncogene

PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma. [Abstract]

2017 Aug 17;36(33):4682-4691. PMID: 28394338
Br J Cancer

PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes. [Abstract]

2024 Jul;131(2):231-242. PMID: 38806724
ACS Appl Mater Interfaces

Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy. [Abstract]

2019 Apr 3;11(13):12342-12356. PMID: 30860347
Cell Rep

PARP1-driven repair of topoisomerase IIIα DNA-protein crosslinks by FEN1. [Abstract]

2024 Jul 18;43(8):114522. PMID: 39028621
Cell Rep

Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages. [Abstract]

2023 Oct 16;42(10):113256. PMID: 37847590
J Med Chem

YCH1899, a Highly Effective Phthalazin-1(2 H)-one Derivative That Overcomes Resistance to Prior PARP Inhibitors. [Abstract]

2023 Sep 14;66(17):12284-12303. PMID: 37605459
Cancer Cell Int

WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment. [Abstract]

2023 Jun 27;23(1):128. PMID: 37370065
Mol Cancer Ther

Harnessing senolytics and PARP inhibition to expand the antitumor activity of CDK4/6 inhibitors in prostate cancer. [Abstract]

2025 Jul 2. PMID: 40601842
Sustain Chem Pharm

2026 Feb 9.
Biochem Pharmacol

Discovery of Bi-magnolignan as a novel BRD4 inhibitor inducing apoptosis and DNA damage for cancer therapy. [Abstract]

2025 May:235:116843. PMID: 40024351
Cell Biosci

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids. [Abstract]

2024 Feb 6;14(1):20. PMID: 38321470
Bioeng Transl Med

Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer. [Abstract]

2019 Jun 14;4(2):e10131. PMID: 31249881
Drug Des Devel Ther

Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies. [Abstract]

2020 Feb 25:14:783-793. PMID: 32158196
Oncogenesis

STAG2 expression imparts distinct therapeutic vulnerabilities in muscle-invasive bladder cancer cells. [Abstract]

2025 Mar 1;14(1):4. PMID: 40025053
Radiother Oncol

X-ray on chip: Quantifying therapeutic synergies between radiotherapy and anticancer drugs using soft tissue sarcoma tumor spheroids. [Abstract]

2021 Apr:157:175-181. PMID: 33516789
Biomolecules

Co-Inhibition of PARP and STAT3 as a Promising Approach for Triple-Negative Breast Cancer. [Abstract]

2025 Jul 17;15(7):1035. PMID: 40723906
Int J Mol Sci

Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study. [Abstract]

2022 Nov 18;23(22):14338. PMID: 36430819
Int J Mol Sci

Establishment and Characterization of a Brca1-/-, p53-/- Mouse Mammary Tumor Cell Line. [Abstract]

2020 Feb 11;21(4):1185. PMID: 32053991
Bioinformatics

Automatic DNA replication tract measurement to assess replication and repair dynamics at the single molecule level. [Abstract]

2022 Sep 15;38(18):4395-4402. PMID: 35881697
Mol Pharm

2026 Jun 8.
Int J Cancer

PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma. [Abstract]

2024 Jul 15;155(2):203-210. PMID: 38619111
Sci Rep

Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer. [Abstract]

2023 Feb 27;13(1):3334. PMID: 36849518
Neoplasia

AsiDNA Treatment Induces Cumulative Antitumor Efficacy with a Low Probability of Acquired Resistance. [Abstract]

2019 Sep;21(9):863-871. PMID: 31362243
Oncol Rep

PI3K p110α inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673. [Abstract]

2019 Nov;42(5):2097-2107. PMID: 31545455
Biomedicines

2026 May;14(5):949.
BMC Cancer

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. [Abstract]

2022 Mar 23;22(1):312. PMID: 35321693
Invest New Drugs

Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers. [Abstract]

2021 Oct;39(5):1213-1221. PMID: 33710464
Front Oncol

The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma. [Abstract]

2021 Jul 9:11:681441. PMID: 34307148
DNA Repair

Loss of the p12 subunit of DNA polymerase delta leads to a defect in HR and sensitization to PARP inhibitors. [Abstract]

2019 Jan:73:64-70. PMID: 30470508
Am J Cancer Res

Novel dual action PARP and microtubule polymerization inhibitor AMXI-5001 powerfully inhibits growth of esophageal carcinoma both alone and in combination with radiotherapy. [Abstract]

2024 Jan 15;14(1):378-389. PMID: 38323288
Genes (Basel)

Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor. [Abstract]

2023 Jun 20;14(6):1295. PMID: 37372475
Am J Cancer Res

AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. [Abstract]

2020 Aug 1;10(8):2649-2676. PMID: 32905466
Biomed Res Int

ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines. [Abstract]

2023 Feb 6:2023:7891753. PMID: 36794257
PLoS One

2026 Apr 3;21(4):e0345514.
PLoS One

Activated NAD+ biosynthesis pathway induces olaparib resistance in BRCA1 knockout pancreatic cancer cells. [Abstract]

2024 Apr 16;19(4):e0302130. PMID: 38625917
FEBS Open Bio

Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP-ribose) glycohydrolase inhibitor. [Abstract]

2025 Dec 5. PMID: 41347713
Biochem Biophys Res Commun

Loss of DNA replication fork protection by TIMELESS degradation supports oncogene-induced senescence. [Abstract]

2025 Aug 30:776:152203. PMID: 40517672
Oncol Lett

DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines. [Abstract]

2025 Jan 7;29(3):128. PMID: 39822940
Integr Biol (Camb)

Long-term fluorescence hyperspectral imaging of on-chip treated co-culture tumour spheroids to follow clonal evolution. [Abstract]

2019 Apr 1;11(4):130-141. PMID: 31172192
Data Brief

Preclinical data on co-delivery of temozolomide and talazoparib by fucodain-coated nanoscale metal organic frameworks for colorectal cancer chemoradiation. [Abstract]

2021 Sep 22:38:107394. PMID: 34632011
Res Connect

2026 May 28.
Duke University

2026.
bioRxiv

Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models. [Abstract]

2026 Feb 18:2026.02.16.706212. PMID: 41757027
bioRxiv

Distinct p21 dynamics drive alternative routes to whole-genome duplication through a common CDK4/6-dependent polyploid G0 state. [Abstract]

2026 Jan 15:2026.01.15.699545. PMID: 41648389
bioRxiv

2026 Jan 13.
Princeton University

2025.
bioRxiv

2025 Dec 5.
bioRxiv

Design and Development of DNA Damage Chemical Inducers of Proximity (DD-CIP) for Targeted Cancer Therapy. [Abstract]

2025 Nov 4:2025.11.03.686423. PMID: 41278667
bioRxiv

Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells. [Abstract]

2025 Sep 30:2025.09.30.679484. PMID: 41256515
bioRxiv

2025 July 08.
University of Pittsburgh

2024.
bioRxiv

Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models. [Abstract]

2024 Nov 26:2024.11.21.624591. PMID: 39605494
bioRxiv

Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer. [Abstract]

2024 Jul 10:2024.07.09.602803. PMID: 39026842
Research Square Preprint

2024 Feb 2.
J Pers Med

Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells. [Abstract]

2023 Aug 27;13(9):1315. PMID: 37763083
bioRxiv

2023 Jun 28.
bioRxiv

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. [Abstract]

2023 Jun 22:2023.06.22.544406. PMID: 38076873
bioRxiv

2023 Apr 17.
Research Square Print

January 4th, 2023.
Oxid Med Cell Longev

Intrinsic ROS Drive Hair Follicle Cycle Progression by Modulating DNA Damage and Repair and Subsequently Hair Follicle Apoptosis and Macrophage Polarization. [Abstract]

2022 Jul 14:2022:8279269. PMID: 35903712
Patent

US20220054606A1.
bioRxiv

April 22, 2021.
University of London

2021 Sep.
Patent

US20210030680A1.
University of Montreal

2020 Jun.
Patent

US20200129476A1
Patent

US20200078369A1
Patent

US20180362972A1.
Patent

US20180263995A1.
Methods Mol Biol

Methods for High-throughput Drug Combination Screening and Synergy Scoring. [Abstract]

2018:1711:351-398. PMID: 29344898

溶剤 & 溶解度

体外:

DMSO : 25 mg/mL (65.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6292 mL

13.1458 mL

26.2916 mL

5 mM

0.5258 mL

2.6292 mL

5.2583 mL

10 mM

0.2629 mL

1.3146 mL

2.6292 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: 1.25 mg/mL (3.29 mM); Suspended solution; Need ultrasonic

Protocol 3

Add each solvent one by one: 2% DMSO 40% PEG300 5% Tween-80 53% Saline

Solubility: ≥ 0.5 mg/mL (1.31 mM); Clear solution

Protocol 4

Add each solvent one by one: 1% DMSO 99% Saline

Solubility: ≥ 0.25 mg/mL (0.66 mM); Clear solution

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMAc 6% Solutol HS-15 84% PBS

Solubility: 5 mg/mL (13.15 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Wang B, et al. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J Med Chem. 2016 Jan 14;59(1):335-57. [Content Brief]

[2]. Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.Clin Cancer Res. 2013 Sep 15;19(18):5003-15. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6292 mL	13.1458 mL	26.2916 mL	65.7289 mL
	5 mM	0.5258 mL	2.6292 mL	5.2583 mL	13.1458 mL
	10 mM	0.2629 mL	1.3146 mL	2.6292 mL	6.5729 mL
	15 mM	0.1753 mL	0.8764 mL	1.7528 mL	4.3819 mL
	20 mM	0.1315 mL	0.6573 mL	1.3146 mL	3.2864 mL
	25 mM	0.1052 mL	0.5258 mL	1.0517 mL	2.6292 mL
	30 mM	0.0876 mL	0.4382 mL	0.8764 mL	2.1910 mL
	40 mM	0.0657 mL	0.3286 mL	0.6573 mL	1.6432 mL
	50 mM	0.0526 mL	0.2629 mL	0.5258 mL	1.3146 mL
	60 mM	0.0438 mL	0.2191 mL	0.4382 mL	1.0955 mL

Keywords

Talazoparib

106 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Talazoparib

Anti-COVID-19 Compound Library

Orally Active Compound Library

Chemical Probe Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Anti-Prostate Cancer Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radiosensitizer Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Anti-Aging Compound Library Mini

Epigenetics Compound Library Mini

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

MedChemExpress（MCE）の使用を引用している文献 Talazoparib

PARP アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (106)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Talazoparib

Anti-COVID-19 Compound Library

Orally Active Compound Library

Chemical Probe Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Anti-Prostate Cancer Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radiosensitizer Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Anti-Aging Compound Library Mini

Epigenetics Compound Library Mini

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

MedChemExpress（MCE）の使用を引用している文献 Talazoparib

PARP アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (106)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Talazoparib 関連分類

HY-16106 関連分類